CCL

Összesen 15 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM005896
Első szerző:Bajnok László (belgyógyász)
Cím:Relationship of serum resistin level of traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index / Bajnok L., Seres I., Varga Zs., Jeges S., Peti A., Karányi Zs., Juhász A., Csongrádi É., Mezősi E., Nagy E. V., Paragh Gy.
Dátum:2008
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Experimental and Clinical Endocrinology and Diabetes. - 116 : 10 (2008), p. 592-599. -
További szerzők:Seres Ildikó (1954-) (biokémikus) Varga Zsuzsa (1951-) (biokémikus, nephrológus) Jeges Sára Peti Attila Karányi Zsolt (1961-) (biostatisztikus, bioinformatikus) Juhász Attila (1970-) (szakorvos, klinikai mikrobiológus) Csongrádi Éva (1969-) (szakorvos) Mezősi Emese Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Paragh György (1953-) (belgyógyász)
Internet cím:elektronikus változat
DOI
Borító:

2.

001-es BibID:BIBFORM073014
Első szerző:Berta Eszter (belgyógyász)
Cím:Early stage Graves' disease is uniformly accompanied by orbital immune activity even in patients who fail to develop orbithopathy during follow-up / Eszter Berta, Miklós Bodor, László Galuska, György Paragh, Annamária Erdei, Annamária Gazdag, Bernadett Ujhelyi, Ervin Berényi, Mónika Katkó, Andrea Gazsó, Endre V. Nagy
Dátum:2018
ISSN:0947-7349
Megjegyzések:Purpose. Graves' orbitopathy (GO) is a complication of Graves' disease (GD), the development of which cannot be predicted at the time of diagnosis of GD. Our aims were (i) to test if orbital 99mTc-labelled diethylenetriamine pentaacetic acid single-photon emission computer tomography (DTPA SPECT) can predict development of GO later during the course of the disease and (ii) to study whether orbital immune activity can be detected in GD patients who do not develop GO during follow-up.Methods. Fifty-four orbits of 27 patients with newly diagnosed GD were entered into the case-control study. Individuals showing signs of GO at enrolment were excluded. During the two-year follow up, eye signs were recorded every 3 months. Orbital DTPA uptakes on SPECT images were measured when entering the study and at the end of the follow-up period, or when clinical signs of GO developed, whichever occurred first.Results. During thefollow up, 6 patients (22%) were diagnosed with GO. There was no significant difference between the initial DTPA uptakes of the patients with or without later developing GO (10.45?1.72 MBq/cm vs. 9.18?1.18 MBq/cm3 respectively). However, the DTPA uptakes of both GD groups (ie. with and without GO) were higher than that of the control group (7.45?1.36 MBq/cm3, p<0.05).Conclusions. We have shown that GD is accompanied by moderate orbital immune activity in GD patients without GO, irrespective of later development of GO. Why this orbital autoimmunity remains subclinical in the majority of the cases, and progresses into clinically detectable GO in others, remains unclear.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
pajzsmirigy
endokrin orbitopathia
Megjelenés:Experimental And Clinical Endocrinology & Diabetes. - 126 : 10 (2018), p. 628-631. -
További szerzők:Bodor Miklós (1969-) (belgyógyász, endokrinológus) Galuska László (1946-) (belgyógyász, izotópdiagnoszta) Paragh György (1953-) (belgyógyász) Erdei Annamária (1976-) (belgyógyász) Gazdag Annamária (1979-) (belgyógyász) Ujhelyi Bernadett (1981-) (szemész) Berényi Ervin (1964-) (radiológus) Katkó Mónika (1980-) (biológus) Gazsó Andrea Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM042783
035-os BibID:PMID:12161484
Első szerző:Delmas, Pierre D.
Cím:Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis : four-year results from a randomized clinical trial / Pierre D. Delmas, Kristine E. Ensrud, Jonathan D. Adachi, Kristine D. Harper, Somnath Sarkar, Carlo Gennari, Jean-Yves Reginster, Huibert A. P. Pols, Robert R. Recker, Steven T. Harris, Wentao Wu, Harry K. Genant, Dennis M. Black, Richard Eastell, Mulitple Outcomes of Raloxifene Evaluation (MORE) Investigators
Dátum:2002
ISSN:0167-6806
Megjegyzések:The Multiple Outcomes of Raloxifene Evaluation trial studied 7705 postmenopausal women with osteoporosis randomized to placebo, or raloxifene 60 or 120 mg/d [JAMA 282(1999): 637]. This report assesses the efficacy of raloxifene on the long-term cumulative incidence new vertebral fractures through 4 yr. New vertebral fractures was assessed from radiographs taken at baseline, yr 2-4. The primary analysis was the cumulative incidence of new vertebral fractures through 4 yr. A posthoc analysis compared the vertebral fracture risk in yr 4 alone with that observed in the first 3 yr. The 4-yr cumulative relative risks (RR) for one or more new vertebral fractures were 0.64 [95% confidence interval (CI) 0.53, 0.76] with raloxifene 60 mg/d and 0.57 (95% CI 0.48, 0.69) with raloxifene 120 mg/d. In yr 4 alone, raloxifene 60 mg/d reduced the new vertebral fracture risk by 39% [RR 0.61 (95% CI 0.43, 0.88)], which was not found to be significantly different from the RR observed in the first 3 yr in both raloxifene groups, irrespective of prevalent fracture status. The nonvertebral fracture risk was not significantly reduced [RR 0.93 (95% CI 0.81, 1.06)]. The safety profile after 4 yr was similar to that observed after 3 yr. Raloxifene 60 and 120 mg/d through 4 yr decreased the cumulative risk of new vertebral fractures in postmenopausal women with osteoporosis. The decreased vertebral fracture risk in yr 4 alone was not different from that observed in the first 3 yr.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
külföldön készült közlemény
Megjelenés:The Journal of Clinical Endocrinology and Metabolism. - 87 : 8 (2002), p. 3609-3617. -
További szerzők:Ensrud, Kristine E. Adachi, Jonathan D. Harper, Kristine D. Sarkar, Somnath Gennari, Carlo Reginster, Jean-Yves Pols, Huibert A. P. Recker, Robert R. Harris, Steven T. Wu, Wentao Genant, Harry K. Black, Dennis M. Eastell, Richard Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos) The Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM017859
Első szerző:Gazdag Annamária (belgyógyász)
Cím:Improved endothelial function and lipid profile compensate for impaired hemostatic and inflammatory status in iatrogenic chronic subclinical hyperthyroidism of thyroid cancer patients on L-t4 therapy / Gazdag A., Nagy E. V., Burman K. D., Paragh Gy., Jenei Z.
Dátum:2010
Megjegyzések:We aimed to compare the changes of endothelial function and haemostatic, inflammatory and metabolic parameters of short-term iatrogenic hypothyroidism to the characteristics of subclinical hyperthyroidism in patients with differentiated thyroid cancer. DESIGN: Twenty four women (mean age 42.4+/-8.1 years) had undergone total thyroidectomy and radioiodine ablation in treatment for differentiated thyroid cancer. We measured serum thyroglobulin, thyroid function, plasma levels of lipid parameters, homocystine, C-reactive protein, fibrinogen, von Willebrandt factor activity (vWF), nitric oxide, as well as flow-mediated vasodilatation (FMD) and nitroglycerin-mediated vasodilatation of the brachial artery during iatrogenic hypothyroidism (TSH 89.82+/-29.36 mU/L) and again in the same patients during subclinical hyperthyroidism secondary to exogenous levothyroxine administration (TSH 0.24+/-0.11 mU/L). RESULTS: In hypothyroidism, FMD was markedly lower than in subclinical hyperthyroidism (6.79+/-4.44 vs. 14.37+/-8.33%, p<0.005). Total cholesterol (7.34+/-1.23 vs. 4.75+/-1.14 mmol/L, p<0.001), LDL-cholesterol (4.55+/-1.10 vs. 2.70+/-0.89 mmol/L, p<0.005) and homocystine (12.95+/-4.49 vs. 9.62+/-2.29 micromol/L, p<0.005) were significantly higher in hypothyroidism. There was no difference in nitroglycerin-mediated vasodilatation, blood pressure, serum triglyceride and HDL-cholesterol levels according to thyroid function. Fibrinogen (3.23+/-0.50 vs. 4.01+/-0.84 g/L, p<0.005), vWF (90.09+/-25.92 vs.130.63+/-29.97%, p<0.001), C-reactive protein (4.39+/-5.16 vs. 5.55+/-5.15 mg/L, p<0.001) and plasma nitric oxide (24.56+/-6.71 vs. 32.34+/-7.0 micromol/L, <0.005) values were significantly lower in hypothyroidism. FMD correlated in a positive manner with fibrinogen, vWF and nitrogen oxide. CONCLUSIONS: Chronic subclinical hyperthyroidism was associated with improved endothelial function and lipid profile, while haemostatic and inflammatory parameters were impaired. The two opposite mechanisms may well compensate for each other at the level of the vessel wall.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Experimental and Clinical Endocrinology & Diabetes 118 : 6 (2010), p. 381-387. -
További szerzők:Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Burman, Kenneth D. Paragh György (1953-) (belgyógyász) Jenei Zoltán (1968-) (belgyógyász)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

5.

001-es BibID:BIBFORM114373
035-os BibID:(WoS)001004122600001 (Scopus)85168485988
Első szerző:Gerszi Dóra
Cím:Risk Estimation of Gestational Diabetes Mellitus in the First Trimester / Dóra Gerszi, Gergő Orosz, Marianna Török, Balázs Szalay, Gellért Karvaly, László Orosz, Judit Hetthéssy, Barna Vásárhelyi, Olga Török, Eszter M. Horváth, Sabolcs Várbíró
Dátum:2023
ISSN:0021-972X
Megjegyzések:Purpose: There is no early - first trimester- risk estimation available to predict later (gestational week 24-28) gestational diabetes mellitus (GDM) - however it would be beneficial to start an early treatment to prevent the development of complications.We aimed to identify early, first trimester prediction markers for GDM. Methods: The present case-control study is based on the study cohort of a Hungarian biobank containing the biological samples and follow-up data from 2545 pregnant women. Oxidative-nitrative stress-related parameters, steroid hormone, and metabolite levels were measured in the serum/plasma samples collected at the end of the first trimester from 55-55 randomly selected control and later GDM women. Results: Pregnant women, who developed GDM later during the pregnancy were older and had higher body mass indexes (BMI). The following parameters showed higher concentration in their serum/plasma samples: fructosamine, total antioxidant capacity (TAC), testosterone, cortisone, 21-deoxycortisol; while soluble urokinase plasminogen activator receptor (SuPAR), dehydroepiandrosterone sulfate (DHEAS), dihydrotestosterone (DHT), cortisol and 11-deoxycorticosterone levels were lower. Analyzing these variables using a forward stepwise multivariate logistic regression model we established a GDM prediction model with a specificity of 96.6% and sensitivity of 97.5% (included variables: fructosamine, cortisol, cortisone, 11-deoxycorticosterone, SuPAR). Conclusions: Based on these measurements we accurately predict the development of later onset GDM (24th-28th weeks of pregnancy). Early risk estimation provides the opportunity for targeted prevention and the timely treatment of GDM. Prevention and slowing the progression of GDM result in a lower lifelong metabolic risk for both mother and offspring.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
GDM
early risk estimation
first trimester
oxidative-nitrative stress
steroid metabolites
Megjelenés:Journal Of Clinical Endocrinology & Metabolism. - 108 : 11 (2023), p. e1214-e1223. -
További szerzők:Orosz Gergő Balázs (1985-) (szülész-nőgyógyász) Török Marianna Szalay Balázs Karvaly Gellért Orosz László (1984-) (szülész-nőgyógyász) Hetthéssy Judit Vásárhelyi Barna Török Olga (1956-) (szülész-nőgyógyász, humángenetikus) Horváth Eszter Mária Várbíró Szabolcs
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM033124
035-os BibID:PMID:16025395
Első szerző:Győry Ferenc (kardiológus)
Cím:Establishment of the hu-PBL-SCID mouse model for the investigation of thyroid cancer / F. Győry, E. Mezősi, Sz. Szakáll, L. Bajnok, E. Varga, A. Borbély, A. Gazdag, I. Juhász, G. Lukács, E. V. Nagy
Dátum:2005
Megjegyzések:New experimental models of human neoplastic diseases attempt to mimic the human environment that fostered the development of disease in cancer patients. The aim of the present study was to establish a human lymphocyte-engrafted, severe combined immunodeficient (hu-PBL-SCID) mouse model to investigate thyroid cancer and to evaluate the potential use of this model for cancer immunotherapy. Thyroid neoplastic tissues were obtained from ten patients (one follicular adenoma, five papillary, one follicular, one anaplastic and two medullary cancers). One 8 x 4 x 3 millimeter sample from each tumor was cut into two pieces of identical size and transplanted into two SCID mice. In each case, one of the two mice was injected intraperitoneally with lymphocytes from the same tumor patient for the reconstitution of the human immune system (Group A), while the other animal received no lymphocytes (Group B). The engraftment of the tumors was successful in all cases. The growth rate was highly dependent on the histological type. When histologies were compared before implantation and after the removal of the implants, the characters of the tumors proved to be unchanged, except one case where an anaplastic cancer arose from a papillary tumor. Macrophages were present in all but one papillary cancer. All differentiated thyroid cancers were infiltrated by T and B lymphocytes. Lymphocytes and macrophages disappeared from 19/20 grafts by week 16. However, in one case from group A lymphocytes were detected four months after the transplantation. In another case from group A, one papillary cancer spontaneously decreased in size and disappeared. Before implantation, HLA-DR expression was detected in every papillary cancer. HLA-DR expression in the grafts was not seen in 3/5 cases by week 16. In conclusion, an animal model has been established for the investigation of human thyroid cancer, by which the analysis of anti-tumor immunity, as a postulate of immune therapy, may be possible.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Experimental and clinical endocrinology and diabetes 113 : 7 (2005), p. 359-364. -
További szerzők:Mezősi Emese Szakáll Szabolcs (1970-) jr. Bajnok László (1961-) (belgyógyász) Varga E. Borbély A. Gazdag Annamária (1979-) (belgyógyász) Juhász István (1956-) (bőrgyógyász, bőrsebész, kozmetológus, klinikai onkológus) Lukács Géza (1941-) (sebész) Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

7.

001-es BibID:BIBFORM033987
Első szerző:Knüver, Jana
Cím:Thyrotropin-releasing hormone controls mitochondrial biology in human epidermis / Knuever J., Poeggeler B., Gáspár E., Klinger M., Hellwig-Burgel T., Hardenbicker C., Tóth B. I., Bíró T., Paus R.
Dátum:2012
ISSN:0021-972X
Megjegyzések:Context: Mitochondrial capacity and metabolic potential are under the control of hormones, such as thyroid hormones. The most proximal regulator of the hypothalamic-pituitary-thyroid (HPT) axis, TRH, is the key hypothalamic integrator of energy metabolism via its impact on thyroid hormone secretion. Objective: Here, we asked whether TRH directly modulates mitochondrial functions in normal, TRH-receptor-positive human epidermis. Methods: Organ-cultured human skin was treated with TRH (5-100 ng/ml) for 12-48 h. Results: TRH significantly increased epidermal immunoreactivity for the mitochondria-selective subunit I of respiratory chain complex IV (MTCO1). This resulted from an increased MTCO1 transcription and protein synthesis and a stimulation of mitochondrial biogenesis as demonstrated by transmission electron microscopy and TRH-enhanced mitochondrial DNA synthesis. TRH also significantly stimulated the transcription of several other mitochondrial key genes (TFAM, HSP60, and BMAL1), including the master regulator of mitochondrial biogenesis (PGC-1 alpha). TRH significantly enhanced mitochondrial complex I and IV enzyme activity and enhanced the oxygen consumption of human skin samples, which shows that the stimulated mitochondria are fully vital because the main source for cellular oxygen consumption is mitochondrial endoxidation. Conclusions: These findings identify TRH as a potent, novel neuroendocrine stimulator of mitochondrial activity and biogenesis in human epidermal keratinocytes in situ. Thus, human epidermis offers an excellent model for dissecting neuroendocrine controls of human mitochondrial biology under physiologically relevant conditions and for exploring corresponding clinical applications. (J Clin Endocrinol Metab 97: 978-986, 2012)
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of Clinical Endocrinology & Metabolism 97 : 3 (2012), p. 978-986. -
További szerzők:Poeggeler, Burkhard Gáspár E. Klinger, Matthias Hellwig-Burgel, T. Hardenbicker, Celine Tóth István Balázs (1978-) (élettanász) Bíró Tamás (1968-) (élettanász) Paus, Ralf
Internet cím:DOI
elektronikus változat
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM072318
Első szerző:Kocsis Judit (onkológus)
Cím:First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer : efficacy and Safety Analysis / Judit Kocsis, Éva Szekanecz, Ali Bassam, Andrea Uhlyarik, Zsuzsanna Pápai, Gábor Rubovszky, Emese Mezősi, Károly Rucz, Ildikó Garai, Endre Nagy, Iván Uray, Zsolt Horváth
Dátum:2019
Megjegyzések:Background Medullary thyroid cancer (MTC) is a rare disease,the prognosis of advanced and metastatic disease is poor andfew therapeutic options are available in this setting. Based onthe results of phase II and III studies with sorafenib in differentiatedthyroid cancer and the lack of availability of registeredtyrosine kinase inhibitors, vandetabin and cabozantinib in Hungary,we designed a uncontrolled, prospective efficacy andsafety study of patients with metastatic MTC treated with firstlinesorafenib in five Hungarian oncology centers.Methods Ten consecutive patients with progressive or symptomaticmetastatic MTC were included and started sorafenib400 mg twice a day between June 2012 and March 2016. Theprimary end point was median progression-free survival(mPFS). Secondary endpoints included disease control rate,biochemical response, symptomatic response and toxicity.Results Four patients achieved partial remission (40 %) accordingto RECIST 1.1 evaluation. Five patients had stable diseasebeyond 12 months (50 %) and one patient had progressivedisease (10 %). Median PFS was 19.1 months. The disease controlrate was 90 %. Association between radiologic responseand biochemical or symptomatic response was inconsistent.Most common side effects were Grade 1-2 fatigue (60 %),palmar-plantar erythrodysesthesia, rash/dermatitis 50-50 %,alopecia 40 %.Conclusions In our prospective case series in patients withMTC first-line sorafenib showed at least similar efficacy as inother small phase II trials and case reports. Based on comparableefficacy with registered tyrosine kinase inhibitors and it'smanageable toxicity profile, we believe that sorafenib has rolein the sequential treatment of MTC.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Experimental and clinical endocrinology & diabetes. - 127 : 4 (2019), p. 240-246. -
További szerzők:Szekanecz Éva (1968-) (onkológus szakorvos) Bassam, Ali Uhlyarik Andrea Pápai Zsuzsanna Rubovszky Gábor Mezősi Emese Rucz Károly Garai Ildikó (1966-) (radiológus) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Uray Iván Péter (1970-) (kutatóorvos) Horváth Zsolt (1964-) (onkológus, belgyógyász, klinikai farmakológus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM063083
Első szerző:Lábadi Árpád
Cím:Loss-of-Function Variants in a Hungarian Cohort Reveal Structural Insights on TSH Receptor Maturation and Signaling / Lábadi Árpád, Grassi, Elisa Stellaria, Gellén Balázs, Kleinau Gunnar, Biebermann Heike, Ruzsa Beáta, Gelmini, Giulia, Rideg Orsolya, Miseta Attila, Kovács Gábor L., Patócs Attila, Felszeghy Enikő, Nagy Endre V., Mezősi Emese, Persani, Luca
Dátum:2015
ISSN:0021-972X
Megjegyzések:CONTEXT:Congenital hypothyroidism (CH) is one of the most common inborn endocrine disorders with genetic background. Despite the well-established newborn CH screening program in Hungary, no systematic examination of the underlying genetic alterations has been performed as yet.OBJECTIVE:We aimed to explore TSH receptor (TSHR) mutations in a cohort of Hungarian patients with CH.PATIENTS:Eighty-five unrelated patients with permanent primary CH, all diagnosed at newborn screening, were selected.MAIN OUTCOME MEASURES:Coding exons of the TSHR gene were sequenced and evaluated together with the thyroid-specific clinical parameters. Functional features of the novel mutations were experimentally examined, and their comparative molecular models were built.RESULTS:In four patients (one heterozygous and three compound heterozygous), seven TSHR mutations were identified. Among these, N432(1.50)D and P449(2.39)L are novel missense alterations. Importantly, the N432(1.50) residue is highly conserved among G protein-coupled receptors, and its function has not been examined yet in human glycoprotein hormone receptors. Our results indicate that the N432(1.50)D mutation disrupts important, architecture-stabilizing intramolecular interactions and ultimately leads to the complete intracellular retention of the receptor. On the other hand, P449(2.39) is located in the intracellular part of the receptor, which is important in G protein coupling. The P449(2.39)L mutation results in signaling impairment, with a more profound effect on the Gq/11 pathway.CONCLUSION:TSHR mutations are common among Hungarian patients with CH. The novel genetic alterations revealed an important structural role of the N432(1.50) and the P449(2.39) residues in receptor expression and signaling, respectively.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Congenital hypothyroidism
TSH receptor
newborn CH screening program
Megjelenés:Journal Of Clinical Endocrinology & Metabolism. - 100 : 7 (2015), p. E1039-E1045. -
További szerzők:Grassi, Elisa Stellaria Gellén Balázs Kleinau, Gunnar Biebermann, Heike Ruzsa Beáta Gelmini, Giulia Rideg Orsolya Miseta Attila Kovács Gábor L. (Szeged) Patócs Attila Felszeghy Enikő Noémi (1970-) (gyermekgyógyász) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Mezősi Emese Persani, Luca
Pályázati támogatás:RF-2010-2309484
Egyéb
KL2334/2-2
Egyéb
BI 893/6-3
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM012184
Első szerző:Lajszné Tóth Beáta (molekuláris biológus)
Cím:Novel sequence variation of AIRE and detection of interferon-omega antibodies in early infancy / Tóth B., Wolff B. S. A., Halász Z., Tar A., Szüts P., Ilyés I., Erdos M., Szegedi G., Housebye E. S., Zeher M., Maródi L.
Dátum:2010
ISSN:0300-0664 1365-2265
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Clinical Endocrinology. - 72 : 5 (2010), p. 641-647. -
További szerzők:Wolff, Anette S. B. Halász Zita Tar Attila Szüts Péter Ilyés István (1943-) (gyermekgyógyász, gyermekendokrinológus, háziorvos) Erdős Melinda (1975-) (infektológus, gyermekimmunológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Housebye, Eystein S. Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Maródi László (1949-) (gyermekgyógyász infektológus, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

11.

001-es BibID:BIBFORM050268
Első szerző:Lőrincz Hajnalka (biológus)
Cím:Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects / Hajnalka Lőrincz, Mónika Katkó, Mariann Harangi, Sándor Somodi, Krisztina Gaál, Péter Fülöp, György Paragh, Ildikó Seres
Dátum:2014
ISSN:0300-0664
Megjegyzések:OBJECTIVE: Chemerin is a recently described adipokine expressed primarily in the white adipose tissue. Compared with lean subjects, circulating chemerin levels are significantly elevated in obese individuals and correlate positively with the prevalence of various cardiovascular risk factors including altered lipoprotein levels. To date, the impact of chemerin on lipoprotein subfractions and its role in atherosclerotic processes are still unclear. PATIENTS AND METHODS: Fifty nondiabetic obese (NDO) patients and 38 lean controls matched in age and gender were enrolled. Chemerin level was measured by ELISA. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions were detected by nongradient polyacrylamide gel electrophoresis (Lipoprint). RESULTS: We detected significantly higher serum chemerin levels in NDO patients compared with healthy controls (590·1 ± 190·3 ng/ml vs 405 ± 127·1 ng/ml, P < 0·001). A significant positive correlation was found between chemerin and LDL cholesterol levels, while chemerin showed a significant negative correlation with the level of HDL cholesterol. Significant positive correlation was detected between chemerin and the ratio of small dense LDL, while chemerin correlated negatively with the mean LDL size. Also, a significant negative correlation was found between serum chemerin and the ratio of large HDL subfraction, while there were significant positive correlations between chemerin levels and intermediate and small HDL subfraction ratios, respectively. CONCLUSION: Chemerin may be involved in the regulation of lipoprotein metabolism in obese patients who do not show apparent abnormalities of glucose metabolism. Early changes in the distribution of the lipoprotein subfractions may contribute to the progression of atherosclerosis, leading to increased cardiovascular risk.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
nondiabetic obese
Low-density lipoprotein
LDL cholesterol
Megjelenés:Clinical Endocrinology. - 81 : 3 (2014), p. 370-377. -
További szerzők:Katkó Mónika (1980-) (biológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Somodi Sándor (1977-) (belgyógyász) Gaál Krisztina (1976-) (belgyógyász szakorvos) Fülöp Péter (1974-) (belgyógyász, endokrinológus, lipidológus) Paragh György (1953-) (belgyógyász) Seres Ildikó (1954-) (biokémikus)
Pályázati támogatás:TÁMOP-4.2.2.A-11/1/KONV-2012-0031
TÁMOP
84196
OTKA
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM087248
Első szerző:Molnár Ildikó (belgyógyász, endokrin, immun- és allergológiai szakorvos)
Cím:Hyperthyroidism in Patients with Graves' Ophthalmopathy, and Thyroidal, Skeletal and Eye Muscle Specific Type 2 Deiodinase Enzyme Activities / Ildikó Molnár, József A. Szentmiklósi, Éva Somogyiné-Vári
Dátum:2017
ISSN:0947-7349 1439-3646
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Experimental And Clinical Endocrinology & Diabetes. - 125 : 8 (2017), p. 514-521. -
További szerzők:Szentmiklósi József András (1948-) (farmakológus, klinikai laboratóriumi szakorvos) Somogyiné-Vári Éva
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2